Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
Authors
Keywords
-
Journal
PLoS One
Volume 7, Issue 3, Pages e33797
Publisher
Public Library of Science (PLoS)
Online
2012-03-31
DOI
10.1371/journal.pone.0033797
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
- (2011) Jan Thöne et al. AMERICAN JOURNAL OF PATHOLOGY
- Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
- (2011) R. A. Linker et al. BRAIN
- Insight into the mechanism of laquinimod action
- (2011) W. Brück et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation
- (2011) Laura Codarri et al. NATURE IMMUNOLOGY
- The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF
- (2011) Mohamed El-Behi et al. NATURE IMMUNOLOGY
- PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages duringchronic hepatitis C virus infection
- (2010) Cheng J. Ma et al. IMMUNOLOGY
- Interleukin-27 Induces a STAT1/3- and NF-κB-dependent Proinflammatory Cytokine Profile in Human Monocytes
- (2010) Christina Guzzo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
- (2010) Christiane Wegner et al. JOURNAL OF NEUROIMMUNOLOGY
- Updates on the Treatment of Lupus Nephritis
- (2010) A. S. Bomback et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
- (2010) G. Comi et al. Multiple Sclerosis Journal
- The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
- (2009) Howard L. Weiner ANNALS OF NEUROLOGY
- Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system
- (2009) Ulf Schulze-Topphoff et al. NATURE MEDICINE
- Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
- (2009) Per Björk et al. PLOS BIOLOGY
- Distinct and Nonredundant In Vivo Functions of IFNAR on Myeloid Cells Limit Autoimmunity in the Central Nervous System
- (2008) Marco Prinz et al. IMMUNITY
- Cytokine Signaling Modules in Inflammatory Responses
- (2008) John J. O'Shea et al. IMMUNITY
- The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice
- (2008) Beichu Guo et al. JOURNAL OF CLINICAL INVESTIGATION
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) G Comi et al. LANCET
- Tempering antigen-presenting cells in multiple sclerosis
- (2008) Thomas Prod'homme et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search